Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer therapeutic candidates and supply chain quality, leading to investor losses during the specified Class Period [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result, statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased or acquired Telix shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=180007&from=3 CLASS PE ...

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=179984&from=4 CLASS PERIO ...

Core Insights - Telix Pharmaceuticals has announced a strategic clinical collaboration with Varian, a Siemens Healthineers company, to develop novel clinical applications that integrate Telix's theranostic products with external beam radiation therapy (EBRT) [1][2]. Group 1: Collaboration Details - The collaboration aims to enhance the role of EBRT in cancer treatment by integrating therapeutic radiopharmaceuticals and precision diagnostics, potentially improving patient selection and targeted treatment delivery [2][4]. - The initial focus will be on PSMA-PET imaging for prostate cancer radiotherapy patients, utilizing Telix's Gozellix® and Illuccix® products to develop personalized treatment plans and monitor treatment responses [3][4]. Group 2: Future Opportunities - The partnership is structured as a general framework for future co-development opportunities, which may include other PET imaging candidates in Telix's pipeline, such as TLX250-CDx and TLX101-CDx, as well as future therapeutic radiopharmaceuticals [4]. - By combining Telix's expertise in molecular imaging with Varian's leadership in radiation therapy, the collaboration aims to advance personalized cancer care and improve patient outcomes [5]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in multiple countries [20]. - Varian, as a Siemens Healthineers company, has over 75 years of experience in developing technologies for cancer treatment, supporting various stages of the cancer care journey [22].

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 21, 2025, to August 28, 2025, Telix Pharmaceuticals made materially false and misleading statements regarding its prostate cancer therapeutic candidates [3]. - It is claimed that the company overstated the progress made with its therapeutic candidates and the quality of its supply chain and partners [3]. - As a result of these misstatements, the company's statements about its business, operations, and prospects were deemed materially false and misleading [3]. Group 2: Class Action Details - Shareholders who purchased shares of TLX during the class period are encouraged to register for the class action, with a deadline set for January 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to stock inflation [5].

Core Viewpoint - The article discusses a securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misrepresentations regarding the development of its therapeutic candidates and supply chain issues, with a significant stock decline following regulatory setbacks [2][3]. Regulatory Failures - The lawsuit highlights two major regulatory events that allegedly corrected market perceptions of Telix's business: - On July 22, 2025, Telix disclosed an SEC subpoena related to its prostate cancer therapeutic candidates, which raised concerns about misleading disclosures on drug development progress [4]. - On August 28, 2025, the FDA rejected the Zircaix application, citing deficiencies in Chemistry, Manufacturing, and Controls (CMC) and documented Form 483 deficiencies at third-party manufacturers [4]. Stock Impact - Following these regulatory revelations, Telix's American Depositary Shares (ADSs) experienced a sharp decline, with a total stock drop of 21% after the final regulatory news [2][4]. Legal Issues - The complaint raises key legal issues, including whether Telix made misleading disclosures regarding drug development progress and whether the company concealed foundational weaknesses in its third-party supply chain and manufacturing processes [4]. Investor Actions - Hagens Berman, the law firm leading the litigation, is actively advising investors who purchased TLX ADSs during the class period and suffered losses due to undisclosed supply chain and therapeutic progress flaws [5]. Important Dates - The deadline for investors to move the court for appointment as lead plaintiff in the lawsuit is January 9, 2026 [1][6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 8, 2025) ...

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=179723&from=4 CLASS PERIOD ...